Drugs / Tusamitamab ravtansine
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05429762 | Oct 2022 → Aug 2023 | neoplasm | Sanofi | Terminated | No outcome recorded |
| Phase 1 | NCT03324113 | Oct 2017 → Nov 2022 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02187848 | Jul 2014 → Nov 2020 | cancer | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 27 trials | ||||||
| Phase 2 | NCT05703555 | Feb 2024 | breast cancer, gastric cancer, lung carcinoma | Erasmus Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT05849246 | Jul → Nov 2023 | non-small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05245071 | Jun 2022 → Mar 2024 | non-small cell lung carcinoma | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05071053 | Nov 2021 → Jun 2023 | gastric adenocarcinoma, gastroesophageal cancer | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04659603 | Mar 2021 → Feb 2024 | breast carcinoma, pancreatic adenocarcinoma | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04524689 | Oct 2020 → Mar 2024 | non-small cell lung carcinoma | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04394624 | Aug 2020 → Mar 2023 | non-small cell lung carcinoma | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04154956 | Feb 2020 → Sep 2023 | non-small cell lung carcinoma | Sanofi | Terminated | Missed primary Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-21 | Sanofi | Results Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint sanofi.com ↗
An Independent Data Monitoring Committee (IDMC) found that tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-21 | Sanofi | Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint sanofi.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tusamitamab ravtansine | “Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors:...” PMID 35026412 ↗ Jan 20227“SAR408701 (tusamitamab ravtansine)” NCT04154956 ↗ |
| Known as | Maytansin-loaded anti-ceacam5 mab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298098 ↗ |
| Known as | SAR408701 | “Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate composed of a humanized monoclonal antibody” PMID 35026412 ↗ Jan 20225“Tusamitamab ravtansine (SAR408701)” NCT05071053 ↗ |
| Action | Deplete | “a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells” PMID 35026412 ↗ Jan 2022 |
| Modality | Other / unclassified | “Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion...” PMID 35026412 ↗ Jan 2022 |
| Route | Intravenous | “Patients were treated with ascending doses of tusamitamab ravtansine intravenously every 2 weeks (Q2W).” PMID 35026412 ↗ Jan 2022 |
| Target | CEACAM5 | “binds carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)” PMID 40413667 ↗ May 2025 |